Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (OCS) published a notification on March 4, 2026 regarding the vesting and settlement of restricted stock units (RSUs) previously granted to a director. The disclosure names Arshad Khanani and references an RSU vesting event dated 28 February 2026.

Key Figures

RSU vesting date: 28 February 2026

1 metrics

RSU vesting date 28 February 2026 Vesting and settlement of RSUs previously granted to a director

Market Reality Check

Price: $27.72 Vol: Volume 286,264 is slightl...

normal vol

$27.72 Last Close

Volume Volume 286,264 is slightly below the 20-day average of 318,877 (relative volume 0.9x). normal

Technical Price $27.57 is trading above the 200-day MA at $20.51, near the 52-week high of $30.68 and well above the 52-week low of $14.00.

Peers on Argus

OCS fell 3.64% while 2 tracked biotech peers in momentum (ABUS, UPB) also moved ...

2 Down

OCS fell 3.64% while 2 tracked biotech peers in momentum (ABUS, UPB) also moved down (median move about -1.5%), pointing to broader Healthcare/Biotech pressure rather than company-specific selling.

Common Catalyst Sector moves appear driven by broader biotech dynamics; only one peer (EYPT) reported earnings, suggesting today’s action is not centered on a shared news event.

Historical Context

5 past events · Latest: Feb 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 27	Manager RSU vesting	Neutral	-2.7%	Disclosure of RSU vesting and settlement for director Arshad Khanani.
Feb 18	Manager earnout vesting	Neutral	-0.6%	Notifications on vesting of earnout shares and removal of restrictions for managers.
Feb 17	Executive appointment	Positive	+1.0%	Appointment of Chief Legal Officer to lead legal and governance functions.
Jan 08	Pipeline showcase	Positive	+5.0%	J.P. Morgan conference presentation of late-stage ophthalmology pipeline, including Privosegtor.
Jan 06	Breakthrough designation	Positive	+5.8%	FDA Breakthrough Therapy Designation for Privosegtor in optic neuritis.

Pattern Detected

OCS has generally reacted positively to clinical and regulatory milestones, while routine managerial transaction notices have coincided with modest declines.

Recent Company History

Over the last few months, Oculis reported several milestones. Breakthrough Therapy Designation for Privosegtor on Jan 6, 2026 and the J.P. Morgan conference pipeline showcase on Jan 8, 2026 both aligned with 5%+ gains. A Chief Legal Officer appointment on Feb 17, 2026 also saw a mild positive reaction. In contrast, prior notifications of managerial transactions tied to RSU vesting and earnout shares on Feb 18 and Feb 27, 2026 were followed by small declines, similar in nature to today’s RSU-related disclosure.

Regulatory & Risk Context

Active S-3 Shelf · $6,877,246.59

Shelf Active

Active S-3 Shelf Registration 2025-11-10

$6,877,246.59 registered capacity

An effective Form F-3 dated Nov 10, 2025 registers the resale of up to 494,259 ordinary shares issuable under a warrant held by a selling securityholder. Oculis is not selling securities under this prospectus and would only receive up to $6,877,246.59 in cash if the warrant is fully exercised.

Market Pulse Summary

This announcement details the vesting and settlement of RSUs previously granted to a company directo...

Analysis

This announcement details the vesting and settlement of RSUs previously granted to a company director, a routine governance event rather than a business or clinical milestone. In recent months, Oculis has reported more material catalysts, including FDA Breakthrough Therapy Designation for Privosegtor and late-stage pipeline updates that coincided with 5%+ gains. Investors tracking the story may focus more on upcoming Phase 3 DIAMOND results and execution of the PIONEER program than on this administrative disclosure.

Key Terms

rsus, persons discharging managerial responsibilities

2 terms

rsus financial

"The attached notification relates to the vesting and settlement of RSUs previously"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

persons discharging managerial responsibilities regulatory

"Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities"

Persons Discharging Managerial Responsibilities are the key people in a company who make big decisions, like top managers or executives. Knowing who they are is important because their actions can influence the company’s success or failure, and they are often required to share information about their dealings to ensure transparency for investors and the public.

AI-generated analysis. Not financial advice.

ZUG, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Attachment

• Notification of managers' transaction - Arshad Khanani - 28 February 2026 RSU vest

FAQ

What did Oculis (OCS) disclose about Arshad Khanani on March 4, 2026?

Oculis disclosed the vesting and settlement of RSUs previously granted to director Arshad Khanani. According to the company, the notification references an RSU vest event dated 28 February 2026 and confirms the managerial transaction disclosure on March 4, 2026.

When did the RSUs for Arshad Khanani vest according to Oculis (OCS)?

The RSUs vested on 28 February 2026, as referenced in the company's notification. According to the company, the disclosure relates specifically to the vesting and settlement of those previously granted restricted stock units to the director.

Does the Oculis (OCS) notification indicate any cash proceeds or sale by the director?

No cash proceeds or share sale details are disclosed in the notification about the RSU vesting. According to the company, the announcement only covers vesting and settlement of RSUs and does not state any subsequent sales or cash transactions.

Which corporate action did Oculis (OCS) report on March 4, 2026 for insiders?

Oculis reported a managers' transaction notification regarding RSU vesting and settlement for a director. According to the company, the filing documents the administrative vesting event dated 28 February 2026 involving Arshad Khanani.

How should investors interpret the Oculis (OCS) RSU notification dated March 4, 2026?

The notification is an insider disclosure of RSU vesting, not operational or financial guidance. According to the company, it records the vesting and settlement event for a director on 28 February 2026 and offers transparency on managerial transactions.